What does this service help with?
Develop a declaration strategy around substantive equivalence to assist in comparing instrument selection, technical evidence collation, electronic submission and review of responses.
Develop a declaration strategy around substantive equivalence to assist in comparing instrument selection, technical evidence collation, electronic submission and review of responses.
Applicability and scope of work are determined on the basis of products, business activities and available information, and costs and delivery are subject to mutually confirmed project arrangements.
Develop a declaration strategy around substantive equivalence to assist in comparing instrument selection, technical evidence collation, electronic submission and review of responses.
The manufacturer, labeler and team responsible for compliance in the United States market; Specific obligations are judged by the facts of the activities and products of each subject.
Identify information gaps before agreeing on documentation and responsibilities.
Check classification, intended use, applicable 510(k) type versus legal matching devices, sorting differences and evidentiary plans.
Combining applicable information such as product recognition, biocompatibility, electrical safety, software, etc.; Tests and clinical work are organized according to actual need and agreement.
Organization of declarations in the current applicable format and follow-up to inspections, additional information and responses; The result is a FDA decision and no commitment to obtain clearance.
If documents are incomplete, share the product and current stage first. You can provide the remaining details later.
Check products, business roles, existing records and issues to be addressed.
Information gaps, responsibilities of the parties, costs and delivery arrangements are set out on this page.
Collaboration around the assessment, documentation, submission or maintenance of identified issues to be resolved.
Delivery of agreed records or recommendations with clear applicable responsibility for subsequent maintenance.
Registration, listing, submission of or obtaining supporting documents from the database does not amount to FDA approval or full compliance determination. The results of the pre-market declaration are determined by the FDA; Specific exemptions, technical and maintenance requirements should be reconciled with products.
(b) Assessment of comparative equipment, performance and other applicable research materials; Test and document supplementation time is taken separately.
The MDUFA V decision target for application of 510(k) is 95 per cent within 90 FDA review days. The FDA review date is not equal to the total project calendar day, and the suspension, testing and business response of the supplementary information will affect the overall cycle.
FY 2027 Standard application fee US$28,653; The applicable small business has been identified as US$ 7,163. Eligibility for fee reductions is confirmed before application is submitted, and special circumstances such as third-party review are checked separately.
Consulting and filing are quoted separately from FDA fees, based on the number of products, completeness of the records, work scope, response rounds and service term.
The costs of performance, biocompatibility, electrical safety, software, clinical research or other applicable tests and translation are shown separately by product and are not included in the FDA application fee.
Data check: 2026-11-05. The specific application conditions and submission requirements are based on the current official statement of the FDA and the product facts.
Develop a declaration strategy around substantive equivalence to assist in comparing instrument selection, technical evidence collation, electronic submission and review of responses.